Ondansetron–Dexamethasone

Ondansetron–Dexamethasone is not a single biological target but a widely utilized therapeutic drug combination used primarily for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). Ondansetron functions as a competitive antagonist at the 5-HT3 receptor, a ligand-gated ion channel located on vagal nerve terminals and in the area postrema of the brain, effectively blocking the emetic reflex triggered by serotonin release. Dexamethasone is a synthetic corticosteroid that acts as an agonist at the glucocorticoid receptor, providing synergistic antiemetic effects through mechanisms that may include the reduction of inflammation, modulation of the blood-brain barrier, and inhibition of prostaglandin synthesis. Clinical studies have consistently demonstrated that the combination of these two agents is significantly more effective than either drug used alone in controlling acute and delayed emesis. Because this term describes a pharmacological regimen involving two distinct classes of drugs—a serotonin antagonist and a corticosteroid—it does not represent a single protein, enzyme, or receptor target.

Other names

Ondansetron and Dexamethasone combinationOndansetron/Dexamethasone

This entry refers to a drug combination rather than a single molecular target. Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin receptors in the peripheral vagus nerve terminals and the central chemoreceptor trigger zone. Dexamethasone is a potent glucocorticoid that binds to the glucocorticoid receptor, exerting anti-inflammatory and anti-emetic effects, likely through the inhibition of prostaglandin synthesis and reduction of peritumoral inflammation.